[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:t-cell-large-granular-lymphocyte-leukemia:cd3-complex":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"T-Cell Large Granular Lymphocyte Leukemia","CD3 Complex",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05592015","Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia",[12],"Phase 2","RECRUITING","2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.203289Z",{"nct_id":17,"title":18,"phases":19,"status":20,"updated_at":21,"content_modified":22},"NCT07682792","Golidocitinib in Patients With Mycosis Fungoides\u002FSézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:16.454910Z","2026-07-19T19:36:05.150066Z",{"nct_id":24,"title":25,"phases":26,"status":28,"updated_at":29,"content_modified":30},"NCT05998408","JAK1\u002F2 Inhibitor Ruxolitinib for Relapsed\u002FRefractory Immune Bone Marrow Failure",[27],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T02:04:34.624671Z","2026-05-05T02:35:31.872333Z"]